CD274 and neoplasm: Anti-CTLA-4 antibodies as well as PD1 and PD-L1 inhibitors are already approved and used to treat a limited number of tumor types (melanoma and lung cancer), and promising preliminary results indicate potential future use in a large variety of cancers.